Aktienanalyse zu Abeona Therapeutics Inc (ABEO)ABEOAbeona Therapeutics Inc

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Abeona Therapeutics Inc (ABEO) is not a strong buy at the current price of $4.94, despite some positive catalysts. The stock has a low RSI of 29.43, indicating it is oversold, but it has also experienced a 1.79% decline over the past 5 days. The forward P/E ratio is 18.66, suggesting that it may be overvalued compared to its earnings potential. The main risk is the negative net income, which was -20,191,000 USD in the latest quarter, indicating ongoing financial struggles.

8 analysts cover ABEO: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.17.